<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/shutterstock_2578769669-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/shutterstock_2578769669-430x241.jpg"/></p>
<p>巴伐利亚诺迪克是今年最新宣布更换首席执行官的公司。来源：Na_Studio/Shutterstock.com</p>
<p>巴伐利亚诺迪克宣布保罗·查普林将辞去首席执行官职务，这标志着 2026 年制药公司最新的高管变动。</p>
<p>自 2014 年以来一直担任丹麦疫苗专家首席执行官的查普林因个人原因离职。在他的任期内，他监督了巴伐利亚从一家小型研究型公司发展为一家在多个地区拥有批准产品的上市疫苗制造商。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>制药中的化疗：基于铂的癌症药物成分...</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>免疫肿瘤学（IO）- 主题情报</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>查普林将在 2026 年剩余时间内继续担任首席执行官，除非提前找到继任者。公司的董事会目前正在启动寻找新首席执行官的工作。</p>
<p>这位即将离任的高管在一份声明中表示：“我们取得了很多成就，为公司的未来奠定了坚实的基础。我的家人希望搬回澳大利亚，但我仍然全力以赴地支持公司，确保顺利过渡到下一任首席执行官。”</p>
<p>查普林的离职标志着制药公司最近的一次高管变动。道格·英格拉姆上个月透露，他将离开罕见病生物制药公司 Sarepta。在担任首席执行官的十年中，他监督了杜氏肌营养不良症（DMD）疗法的发展，并表示因个人原因将退休。</p>
<p>在 2 月 25 日的投资者电话会议上，英格拉姆表示：“在一个令人震惊且确实讽刺的命运转折中，我对肌营养不良症的个人承诺加深了，因为我直系亲属中的两位成员现在被诊断为肌强直性肌营养不良症 DM1。”</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>由 GlobalData 提供</p>
<p>了解更多关于战略情报</p>
<p>“到 2026 年底，我将有更多时间在加利福尼亚专注于家庭事务，并应对 DM1 的现实。”</p>
<p>英格拉姆的继任者将面临不小的挑战。Sarepta 在其 DMD 基因疗法 Elevidys（delandistrogene moxeparvovec）面临安全和监管问题的情况下经历了动荡的一年。与巴伐利亚诺迪克一样，Sarepta 也开始寻找新首席执行官，英格拉姆将继续留任，直到 2026 年底或找到替代者。</p>
<p>在 2 月初，赛诺菲宣布将不再续约首席执行官保罗·哈德森。自 2025 年 2 月以来，依赖其广泛疫苗组合来获取部分收入的巴黎上市公司赛诺菲，其股价已下跌超过 20%。赛诺菲的领导层变动结束了哈德森六年的任期。</p>
<p>即将离任的默克 KGaA 首席执行官贝伦·加里霍将于 4 月 29 日接任赛诺菲的首席执行官。加里霍自 2021 年起担任默克 KGaA 首席执行官，当时她成为第一位领导大型德国蓝筹公司的女性。尽管加里霍仍然担任高管，但在大型制药公司中女性担任首席执行官的比例有限。</p>
<p>年初，卢克·米尔斯成为 GSK 的新首席执行官，此前艾玛·沃姆斯利正式离开了公司的领导职位。沃姆斯利在 2017 年 4 月加入这家英国制药公司时被认为是第一位女性首席执行官，并宣布将于 2025 年 9 月辞职。</p>
<p>赛诺菲的突然转变类似于 诺和诺德在 2025 年中期的转变，后者在财务表现下滑的情况下与长期首席执行官拉斯·弗鲁尔加德·约根森分道扬镳。马齐亚尔·迈克·杜斯达尔于 2025 年 8 月接任诺和诺德首席执行官。</p>

医疗业 ETF - SPDR

赛诺菲集团

Sarepta医疗

医疗业 ETF - Vanguard

美国制药 ETF - iShares

标普生物技术 ETF - SPDR

<p>巴伐利亚诺迪克的首席执行官保罗·查普林因个人原因辞职，这标志着制药行业的重大变革。查普林自 2014 年以来一直领导公司，监督其成长为一家上市疫苗制造商。他的离职紧随行业内其他首席执行官的更换，包括赛诺菲的保罗·哈德森和 Sarepta 的道格·英格拉姆。英格拉姆因家庭事务退休，而哈德森的合同将在赛诺菲股价下滑后不再续签。两家公司都在进行新首席执行官的寻找，突显出制药行业持续的领导层变动</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/shutterstock_2578769669-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/shutterstock_2578769669-430x241.jpg"/></p>
<p>Bavarian Nordic is the latest company to announce a CEO change this year. Credit: Na_Studio/Shutterstock.com</p>
<div class="lb-trans"><p>巴伐利亚诺迪克是今年最新宣布更换首席执行官的公司。来源：Na_Studio/Shutterstock.com</p>
</div><p>Bavarian Nordic’s announcement that Paul Chaplin will step down as CEO has marked the latest high-profile change at a pharmaceutical company in 2026.</p>
<div class="lb-trans"><p>巴伐利亚诺迪克宣布保罗·查普林将辞去首席执行官职务，这标志着 2026 年制药公司最新的高管变动。</p>
</div><p>Chaplin, who has been at the helm of the Danish vaccine specialist since 2014, is leaving for personal reasons. Over his tenure, he has overseen Bavarian’s development from a small research-based company to a publicly listed vaccine manufacturer with approved products in multiple regions.</p>
<div class="lb-trans"><p>自 2014 年以来一直担任丹麦疫苗专家首席执行官的查普林因个人原因离职。在他的任期内，他监督了巴伐利亚从一家小型研究型公司发展为一家在多个地区拥有批准产品的上市疫苗制造商。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi...</h4>
<div class="lb-trans"><h4>制药中的化疗：基于铂的癌症药物成分...</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>Immuno-oncology (IO) - Thematic Intelligence</h4>
<div class="lb-trans"><h4>免疫肿瘤学（IO）- 主题情报</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>Chaplin will continue to serve as CEO for the remainder of 2026, unless a successor is identified earlier. The company’s board is currently initiating a search for a new CEO.</p>
<div class="lb-trans"><p>查普林将在 2026 年剩余时间内继续担任首席执行官，除非提前找到继任者。公司的董事会目前正在启动寻找新首席执行官的工作。</p>
</div><p>The outgoing exec said in a statement: “We have achieved a lot and created a strong foundation for the future of the company. My family wants to relocate back to Australia, but I remain fully committed to the company for the remainder of the year to allow for a stable transition to its next CEO.”</p>
<div class="lb-trans"><p>这位即将离任的高管在一份声明中表示：“我们取得了很多成就，为公司的未来奠定了坚实的基础。我的家人希望搬回澳大利亚，但我仍然全力以赴地支持公司，确保顺利过渡到下一任首席执行官。”</p>
</div><p>The departure of Chaplin marks the latest in a recent shakeup at pharmaceutical companies. Doug Ingram revealed last month that he will leave rare disease biopharma Sarepta. After a decade overseeing the development of therapies for Duchenne muscular dystrophy (DMD) as CEO, Ingram said he would retire for personal reasons.</p>
<div class="lb-trans"><p>查普林的离职标志着制药公司最近的一次高管变动。道格·英格拉姆上个月透露，他将离开罕见病生物制药公司 Sarepta。在担任首席执行官的十年中，他监督了杜氏肌营养不良症（DMD）疗法的发展，并表示因个人原因将退休。</p>
</div><p>Speaking in an investor call on 25 February, Ingram said: “In a shocking and certainly ironic twist of fate, my personal commitment to muscular dystrophy deepened, as two members of my immediate family have been diagnosed now with myotonic dystrophy, DM1.</p>
<div class="lb-trans"><p>在 2 月 25 日的投资者电话会议上，英格拉姆表示：“在一个令人震惊且确实讽刺的命运转折中，我对肌营养不良症的个人承诺加深了，因为我直系亲属中的两位成员现在被诊断为肌强直性肌营养不良症 DM1。”</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>“By the end of 2026, the time will have come for me to spend more time in California focusing on family commitments and addressing the realities of DM1.”</p>
<div class="lb-trans"><p>“到 2026 年底，我将有更多时间在加利福尼亚专注于家庭事务，并应对 DM1 的现实。”</p>
</div><p>Ingram’s successor will have a far from easy task on their hands. Sarepta has endured a tumultuous past year amid safety and regulatory issues for its DMD gene therapy Elevidys (delandistrogene moxeparvovec). Like Bavarian Nordic, Sarepta has begun a search for a new CEO, and Ingram will stay on until either the end of 2026 or once his replacement is found.</p>
<div class="lb-trans"><p>英格拉姆的继任者将面临不小的挑战。Sarepta 在其 DMD 基因疗法 Elevidys（delandistrogene moxeparvovec）面临安全和监管问题的情况下经历了动荡的一年。与巴伐利亚诺迪克一样，Sarepta 也开始寻找新首席执行官，英格拉姆将继续留任，直到 2026 年底或找到替代者。</p>
</div><p>Earlier in February, Sanofi announced it would not be renewing CEO Paul Hudson’s contract. Since February 2025, Paris-listed Sanofi, which is reliant on its expansive vaccine portfolio for a proportion of its revenue, has seen its share price slump by more than 20%. The leadership change at Sanofi brings a close to a six-year tenure under Hudson.</p>
<div class="lb-trans"><p>在 2 月初，赛诺菲宣布将不再续约首席执行官保罗·哈德森。自 2025 年 2 月以来，依赖其广泛疫苗组合来获取部分收入的巴黎上市公司赛诺菲，其股价已下跌超过 20%。赛诺菲的领导层变动结束了哈德森六年的任期。</p>
</div><p>Outgoing Merck KGaA CEO Belén Garijo is set take the helm at Sanofi from 29 April. Garijo has been CEO at Merck KGaA since 2021 – at the time she became the first woman to lead a major German blue-chip company. Despite Garijo remaining in a top role, female representation in CEO roles at big pharma companies is limited.</p>
<div class="lb-trans"><p>即将离任的默克 KGaA 首席执行官贝伦·加里霍将于 4 月 29 日接任赛诺菲的首席执行官。加里霍自 2021 年起担任默克 KGaA 首席执行官，当时她成为第一位领导大型德国蓝筹公司的女性。尽管加里霍仍然担任高管，但在大型制药公司中女性担任首席执行官的比例有限。</p>
</div><p>At the start of the year, Luke Miels became the new CEO of GSK after Emma Walmsley formally left her position as the company’s leader. Walmsley, who announced she would step down in September 2025, was recognised as the first-ever female CEO of a major pharma company when she joined the British drugmaker in April 2017.</p>
<div class="lb-trans"><p>年初，卢克·米尔斯成为 GSK 的新首席执行官，此前艾玛·沃姆斯利正式离开了公司的领导职位。沃姆斯利在 2017 年 4 月加入这家英国制药公司时被认为是第一位女性首席执行官，并宣布将于 2025 年 9 月辞职。</p>
</div><p>Sanofi’s abrupt pivot resembles the one made by Novo Nordisk in mid-2025, which parted ways with long-time CEO Lars Fruergaard Jørgensen amid declining financial performance. Maziar Mike Doustdar took over the role of Novo Nordisk CEO in August 2025.</p>
<div class="lb-trans"><p>赛诺菲的突然转变类似于 诺和诺德在 2025 年中期的转变，后者在财务表现下滑的情况下与长期首席执行官拉斯·弗鲁尔加德·约根森分道扬镳。马齐亚尔·迈克·杜斯达尔于 2025 年 8 月接任诺和诺德首席执行官。</p>
</div>

随着 CEO 变动的持续，制药行业正在发生变化